WallStreetZenWallStreetZen

NASDAQ: CAI
Caris Life Sciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CAI

Based on 6 analysts offering 12 month price targets for Caris Life Sciences Inc

Min Forecast
$31.00+5.12%
Avg Forecast
$32.33+9.64%
Max Forecast
$34.00+15.29%

Should I buy or sell CAI stock?

Based on 6 analysts offering ratings for Caris Life Sciences Inc.

Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CAI's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CAI as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their CAI stock forecasts and price targets.

CAI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-07-15
lockedlocked$00.00+00.00%2025-07-14
lockedlocked$00.00+00.00%2025-07-14
lockedlocked$00.00+00.00%2025-07-14
lockedlocked$00.00+00.00%2025-07-14
JP Morgan
Top 18%
83
Strong BuyInitiates Coverage On$31.00+5.12%2025-07-14

1 of 1

Forecast return on equity

Is CAI forecast to generate an efficient return?

Company
-8.62%
Industry
12.19%
Market
-14.81%
CAI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CAI forecast to generate an efficient return on assets?

Company
76.82%
Industry
12.99%
CAI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CAI earnings per share forecast

What is CAI's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.93
Avg 2 year Forecast
$0.20
Avg 3 year Forecast
$0.79

CAI revenue forecast

What is CAI's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$590.9M
Avg 2 year Forecast
$980.5M
Avg 3 year Forecast
$1.2B

CAI vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
CDNA$12.60$29.25+132.14%Strong Buy
CHEK$0.65N/AN/A
BDSX$0.38$1.75+355.73%Strong Buy
CSTL$15.32$37.25+143.15%Strong Buy
CAI$29.49$32.33+9.64%Strong Buy
View Top Diagnostic & Research Stocks

Caris Life Sciences Stock Forecast FAQ

Is Caris Life Sciences Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: CAI) stock is to Strong Buy CAI stock.

Out of 6 analysts, 4 (66.67%) are recommending CAI as a Strong Buy, 2 (33.33%) are recommending CAI as a Buy, 0 (0%) are recommending CAI as a Hold, 0 (0%) are recommending CAI as a Sell, and 0 (0%) are recommending CAI as a Strong Sell.

If you're new to stock investing, here's how to buy Caris Life Sciences stock.

What is CAI's earnings growth forecast for 2025-2027?

(NASDAQ: CAI) Caris Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 23.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.71%.

Caris Life Sciences's earnings in 2025 is N/A.On average, 3 Wall Street analysts forecast CAI's earnings for 2025 to be -$264,642,054, with the lowest CAI earnings forecast at -$292,061,841, and the highest CAI earnings forecast at -$224,008,596. On average, 3 Wall Street analysts forecast CAI's earnings for 2026 to be $57,646,769, with the lowest CAI earnings forecast at $8,506,656, and the highest CAI earnings forecast at $110,586,522.

In 2027, CAI is forecast to generate $224,008,596 in earnings, with the lowest earnings forecast at $224,008,596 and the highest earnings forecast at $224,008,596.

What is CAI's revenue growth forecast for 2025-2027?

(NASDAQ: CAI) Caris Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.32%.

Caris Life Sciences's revenue in 2025 is N/A.On average, 1 Wall Street analysts forecast CAI's revenue for 2025 to be $167,558,429,920, with the lowest CAI revenue forecast at $167,558,429,920, and the highest CAI revenue forecast at $167,558,429,920. On average, 1 Wall Street analysts forecast CAI's revenue for 2026 to be $278,011,681,133, with the lowest CAI revenue forecast at $278,011,681,133, and the highest CAI revenue forecast at $278,011,681,133.

In 2027, CAI is forecast to generate $337,331,425,835 in revenue, with the lowest revenue forecast at $337,331,425,835 and the highest revenue forecast at $337,331,425,835.

What is CAI's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: CAI) forecast ROA is 76.82%, which is higher than the forecast US Diagnostics & Research industry average of 12.99%.

What is CAI's Price Target?

According to 6 Wall Street analysts that have issued a 1 year CAI price target, the average CAI price target is $32.33, with the highest CAI stock price forecast at $34.00 and the lowest CAI stock price forecast at $31.00.

On average, Wall Street analysts predict that Caris Life Sciences's share price could reach $32.33 by Jul 15, 2026. The average Caris Life Sciences stock price prediction forecasts a potential upside of 9.64% from the current CAI share price of $29.49.

What is CAI's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CAI) Caris Life Sciences's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that CAI's EPS will be -$0.93 for 2025, with the lowest EPS forecast at -$1.03, and the highest EPS forecast at -$0.79. On average, analysts forecast that CAI's EPS will be $0.20 for 2026, with the lowest EPS forecast at $0.03, and the highest EPS forecast at $0.39. In 2027, CAI's EPS is forecast to hit $0.79 (min: $0.79, max: $0.79).

What is CAI's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: CAI) forecast ROE is -8.62%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.